Table 1.
Patient characteristics
| Characteristics | Value |
|---|---|
| Age (y), mean (SD) | 74 (6.0) |
| Clinical T stage, n (%) | |
| T1 | 13 (56.5) |
| T2 | 3 (13.0) |
| T3 | 6 (26.1) |
| T4 | 1 (4.35) |
| Gleason score, n (%) | |
| 7 | 2 (8.7) |
| 8 | 10 (43.5) |
| 9 | 10 (43.5) |
| 10 | 1 (4.3) |
| Initial PSA level (ng/mL) | |
| Median (range) | 8.7 (3.3-170.4) |
| <10, n (%) | 13 (56.6) |
| 10-20, n (%) | 5 (21.7) |
| >20, n (%) | 5 (21.7) |
| Risk group, n (%) | |
| High risk without nodal involvement | 20 (87.0) |
| High risk with positive node | 3 (13.0) |
| Baseline prostate volume (cm3) | |
| Median (range) | 42 (14-214) |
| Baseline international prostate symptom score | |
| Mean (SD) | 8.7 (6.7) |
| Baseline international index of erectile dysfunction; n = 14 | |
| Median (range) | 18.5 (1-30) |
| Duration of ADT (mo) | |
| Mean (SD) | 13.0 (7.0) |
| <6, n (%) | 3 (13.0) |
| 6-12, n (%) | 10 (43.5) |
| >12, n (%) | 10 (43.5) |
| Radiation dose to prostate and pelvic node, n (%) | |
| 37.5 Gy and 25 Gy | 2 (8.7) |
| 40.0 Gy and 25 Gy | 21 (91.3) |
| Rectal spacer, n (%) | |
| Yes | 5 (21.7) |
| No | 18 (78.3) |
Abbreviations: ADT = androgen deprivation therapy; PSA = prostate-specific antigen; SD = standard deviation.